Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — FY2017 Earnings Presentation

9 slides from Lumos Pharma's earnings presentation, Mar 1, 2018

  1. Slide 1: Fourth Quarter and Year-End 2017 Financial Results

    NewLink Genetics Corporation Nasdaq: NLNK March 1, 2018 Fourth Quarter and Year-End 2017 Financial Results

  2. Slide 2: Agenda

    Agenda 2 Introduction  Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments & Outlook  Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates & Guidance on Timing of Data  Eugene P. Kennedy, M.D., Chief Medical Officer Fourth Quarter and Year-End 2017 Financial

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,

  4. Slide 4: 2017 Highlights

    2017 Highlights  Presented updated Phase 2 data of indoximod plus pembrolizumab indicating encouraging overall and complete responses and progression-free survival  Commenced dose determination portion of Indigo301, a pivotal Phase 3 trial for patients with advanced melanoma  Entered into a colla

  5. Slide 5: 2018 Highlights

    2018 Highlights  Initiate randomization of Indigo301, a pivotal Phase 3 in advanced melanoma in Q2-Q3 2018  Full Phase 2 results of indoximod plus checkpoint inhibitors in metastatic melanoma 1H:2018  Initiate Indigo201, a randomized Phase 2 in metastatic pancreatic cancer in 1H:2018  Full Phase

  6. Slide 6: Indigo301 Phase 3 Trial Design in Advanced Melanoma

    6 • Adults ≥18 years of age with unresectable stage III or IV advanced melanoma • No prior melanoma therapy, except BRAF/MEK inhibitor Prior adjuvant or neoadjuvant therapy ≥4 weeks before randomization Prior adjuvant immunotherapy (no relapse during treatment or ≤6 months of treatment discontinuati

  7. Slide 7: Financial Position

    Financial Position YE 2017 Cash and Equivalents $158.7 million Debt ~$0.3 million YE 2018 Cash (Projected)1 ~$75 million Forecast Quarterly Cash Use ~$20-22 million Shares Outstanding as of December 31,2017 37.1 million 7 1 Excludes projections of proceeds, if any, from potential future financings F

  8. Slide 8: Key Takeaways for 2018

    NewLink Genetics  Initiation of two key randomized trials with indoximod plus checkpoint inhibition – Indigo301 for patients with advanced melanoma – Indigo201 in collaboration with AstraZeneca for patients with metastatic pancreatic cancer  Presentation of results from two Phase 2 trials – Full P

  9. Slide 9: Q & A

    9 Q & A

NewLink Genetics — FY2017 Earnings Presentation on 6ix